Model‐Informed Drug Development for Long‐Acting Injectable Products: Summary of American College of Clinical Pharmacology Symposium-Reference-Cited by-同舟云学术

Model‐Informed Drug Development for Long‐Acting Injectable Products: Summary of American College of Clinical Pharmacology Symposium

Published:2021-02-23 Issue:3 Volume:10 Page:220-228
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Sharan Satish¹,Fang Lanyan¹,Lukacova Viera²,Chen Xiaomei³,Hooker Andrew C.³,Karlsson Mats O.³

Affiliation:

1. Division of Quantitative Methods and Modeling (DQMM), Office of Research and Standards (ORS), Office of Generic Drugs (OGD), Center for Drug Evaluation and Research (CDER) U.S. Food and Drug Administration (FDA) Silver Spring Maryland USA

2. Simulation Sciences Simulations Plus, Inc. Lancaster CA USA

3. Uppsala University Uppsala Sweden

Funder

U.S. Food and Drug Administration

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.928

Reference57 articles.

1. Adherence to Medication

2. Interventions to Improve Adherence to Self-administered Medications for Chronic Diseases in the United States

3. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States

4. Medication Adherence Leads To Lower Health Care Use And Costs Despite Increased Drug Spending

5. Impact of switching to long‐acting injectable antipsychotics on health services use in the treatment of schizophrenia;Lachaine J;Can J Psychiatry,2015

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Bayesian framework for virtual comparative trials and bioequivalence assessments;Frontiers in Pharmacology;2024-07-30

2. Physiologically-Based Pharmacokinetic Modeling and In Vitro–In Vivo Correlation of TV-46000 (Risperidone LAI): Prediction from Dog to Human;Pharmaceutics;2024-07-04

3. Model‐informed Drug Development ( MIDD ) Regarding Regulatory Requirements and Thinking;Exploring Computational Pharmaceutics ‐ AI and Modeling in Pharma 4.0;2024-06-21

4. Development of Mechanistic In Vitro–In Vivo Extrapolation to Support Bioequivalence Assessment of Long-Acting Injectables;Pharmaceutics;2024-04-19

5. Development of a physiologically‐based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs;CPT: Pharmacometrics & Systems Pharmacology;2024-03